Biotechnology Market Size, Share & Trends Analysis Report By Technology (Nanobiotechnology, DNA Sequencing, Cell-based Assays), By Application (Health, Bioinformatics), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global biotechnology market size was estimated at USD 1.37 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 13.96% from 2023 to 2030. The market is driven by a strong government support through initiatives aimed at modernization of regulatory framework, improvements in approval processes & reimbursement policies, as well as standardization of clinical studies. Growing foothold of personalized medicine and an increasing number of orphan drug formulations are opening new avenues for biotechnology applications and are driving the influx of emerging and innovative biotechnology companies, further boosting the market revenue.

The COVID-19 pandemic has positively impacted the biotechnology market by propelling a rise in opportunities and advancements for drug development and manufacturing of vaccines for the disease. For instance, in 2021, over 11 billion doses of COVID-19 vaccine were produced globally, resulting in vaccination of about half of the world’s population within a year. Furthermore, the success of mRNA vaccines and accelerated approval processes have led to a surge in vaccine-related revenues, as evident by a combined revenue generation of around USD 31 billion in 2021 from Moderna, Pfizer/BioNTech, and Johnson & Johnson vaccines.

Expanding demand for biotechnology tools for agricultural applications including micro-propagation, molecular breeding, tissue culturing, conventional plant breeding & development of genetically modified crops, among others, have boosted the market growth. Moreover, genetically modified crops and herbicide-tolerant & insect resistant seeds are witnessing an increasing popularity and are contributing to the market growth. Rise in adoption of tissue culture technology for production of novel rice variants and disease- & pest-free banana varieties in regions of South Asia and Africa, and use of the technology for cloning of disease-free and nutritious plant varieties have propelled the agricultural applications for biotechnology. 

The market is also driven by the presence of strong clinical trial pipeline and funding opportunities available in tissue engineering and regeneration technologies. As per the Alliance for Regenerative Medicine, companies developing cell and gene therapies raised over USD 23.1 billion investments globally in 2021, an increase of about 16% over 2020’s total of USD 19.9 billion. Clinical success of leading gene therapy players in 2021, such as promising results from an in vivo CRISPR treatment for transthyretin amyloidosis, developed by Intellia Therapeutics and Regeneron, are significantly affecting the market growth.

Rising demand for clinical solutions for the treatment of chronic diseases such as cancer, diabetes, age-related macular degeneration, and almost all forms of arthritis are anticipated to boost the market. Major firms are investigating and developing pipeline products for diabetes and neurological disorders, such as Parkinson’s & Alzheimer’s diseases, various types of cancers and cardiovascular diseases. For instance, according to clinicaltrials.gov, as of January 2021, there were 126 agents in clinical trials for the treatment of Alzheimer's disease, with 28 treatments in phase III trials.

Life sciences and healthcare sectors are experiencing a widespread use of fermentation technology and have positively impacted the market growth. Several modifications and advancements in the conventional bioreactors, such as introduction of simplified bioreactors and vortex bioreactors have led to improvements in the fermentation technology and growth in its adoption. Furthermore, vortex bioreactors have also been improvised for wastewater processing, to offer an enhanced operational feasibility. These modifications and improvement in fermentation technology are expected to accelerate market growth in the near future.

CAR T and TCR T-cell therapies are being explored as potential treatment options against chronic viral infections, such as HIV, hepatitis B, and SARS-CoV-2. For instance, scientists at Duke-NUS Medical School are evaluating the use of T-cell therapy in combating the COVID-19 infection. The scientists have demonstrated that TCR-redirected T cells exhibit a functional profile comparable to that of SARS-specific CD8 memory T cells obtained from patients who have recovered from the infection. Such investigations are anticipated to spur further research prospects in this domain and drive the market growth.

Biotechnological techniques including stem cell technology, DNA fingerprinting, and genetic engineering, among other, are gaining significant traction since past few years. Technological advancement in stem cell therapeutics, increasing demand for biologics, and a growing focus on the development of personalized medicines have resulted in a growing market for stem cell technologies. DNA fingerprinting applications are on the rise in forensic science, and for investigation of family relationships in animal populations as well as measurement of the extent of inbreeding. Similarly, genetic engineering and cloning techniques are being increasingly used in animal breeding and for manufacturing of complex biological substances.

Technology Insights

DNA sequencing held a significant market share of 16.51% in 2022 which can be attributed to declining sequencing costs and rising penetration of advanced DNA sequencing techniques. Government funding in genetic research has enabled a rise in applications of sequencing for better understanding of diseases. For instance, in May 2021, a USD 10.7 million NIH grant was awarded to the University of Pittsburgh Graduate School of Public Health and Washington University School of Medicine in St. Louis, for investigation of the genetic basis of Alzheimer’s disease.

Nanobiotechnology is expected to expand at a CAGR of 14.87% from 2023 to 2030 owing to increase in nanomedicine approvals and advent of advanced technology. For instance, applications of theranostics nanoparticles have gained impetus for enabling prompt diagnosis and customization of treatment options for multiple disorders at once. Factors such as low toxicity, smaller size, and chemical plasticity of nanoparticles have proved to be beneficial for overcoming the limitation associated with conventional routes of generic drug administration. Furthermore, tissue engineering and regeneration medicine held a significant share due to government and private investments in the field, along with high healthcare spending and presence of significant number of mature and emerging players in this space. These factors are expected to drive the segment growth over the forecast period.

Application Insights

The health application segment accounted for the largest share of 50.69% in 2022. Growing disease burden, increasing availability of agri-biotech & bio-services, and technological developments in bio-industrial sector are expected to drive the segment growth. In addition, the segment growth is also fueled by significant advancements in the fields of Artificial Intelligence (AI), machine learning, and big data, which are expected to increase penetration of bioinformatics applications, especially in industries such as food and beverages.

Moreover, collaborative efforts and partnerships aimed at development and commercialization of new therapeutic platforms and molecules are anticipated to drive the market growth. For instance, in January 2021, Novartis collaborated with Alnylam for exploring the application of the latter’s siRNA technology for development of targeted therapy for restoration of liver function. Similarly, in September 2021, AstraZeneca and VaxEquity collaborated for development and commercialization of self-amplifying RNA therapeutics platform to explore novel therapeutic programs. Furthermore, growing demand for biosimilars and rising applications of precision medicine are expected to boost segment growth during the forecast period.

Regional Insights

North America accounted for the largest share of 41.63% in 2022. The regional market is witnessing growth due to several factors, such as the presence of key players, extensive R&D activities, and high healthcare expenditure. The region has a high penetration of genomics, proteomics, and cell biology-based platforms that is accelerating the adoption of life sciences tools. Furthermore, rise in prevalence of chronic diseases and rising adoption of personalized medicine applications for the treatment of life threatening disorders is expected to positively impact the market growth in the region.

Asia Pacific is expected to expand at the fastest growth rate of 18.17% from 2023 to 2030. The growth of the regional market can be attributed to increasing investments and improvement in healthcare infrastructure, favorable government initiatives, and expansion strategies from key market players. For instance, in February 2022, Moderna Inc. announced its plans for a geographic expansion of its commercial network in Asia through opening of four new subsidiaries in Malaysia, Singapore, Hong Kong, and Taiwan. In addition, biopharmaceutical collaborations, such as Kiniksa Pharmaceuticals and Huadong Medicine’s strategic collaboration for development and commercialization of Kiniksa’s ARCALYST and mavrilimumab in the Asia-Pacific region are expected to drive the market growth.

Key Companies & Market Share Insights

Biotechnology products have become the vanguard strategy to combat challenges posed by the COVID-19 pandemic. Robust pipeline of companies operating in this industry has helped them sustain the dynamic market competition in 2022.Geographical expansion, strategic partnerships & collaborations, as well as mergers & acquisitions undertaken by these players are fueling the market growth. For Instance, in January 2023, Anima Biotech collaborated with AbbVie to accelerate the development of novel mRNA biology modulators for the treatment of various oncology and immunology targets. Some of the key players in the global biotechnology market include:

• AstraZeneca

• Gilead Sciences, Inc.

• Bristol-Myers Squibb

• Sanofi

• Biogen

• Abbott Laboratories

• Pfizer, Inc.

• Amgen Inc.

• Novo Nordisk A/S

• Merck KGaA

• Johnson & Johnson Services, Inc.

• Novartis AG

• F. Hoffmann-La Roche Ltd.

• Lonza

Recent Development

• In January 2023, Gero and Pfizer entered a strategic research collaboration to harness Pfizer's domain expertise and Gero's advanced technology platform. The partnership aims to identify genes and pathways associated with fibrotic diseases, presenting a remarkable advancement in the biotechnology market by combining a pioneering biotech firm's machine-learning capabilities with a prominent biopharmaceutical company's resources to tackle chronic diseases and age-related conditions

• In May 2023, Gilead Sciences, Inc. revealed its acquisition of XinThera, encompassing all outstanding shares. This strategic move enhances Gilead's clinical development objectives by incorporating complementary pipeline assets focused on validated targets within oncology and inflammation. With access to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases, Gilead further solidifies its leadership position in the biotechnology industry

• In August 2022, Gilead Sciences, Inc. successfully acquired MiroBio, gaining access to their exclusive biotechnology discovery platform and comprehensive portfolio of immune inhibitory receptor agonists. The integration of MiroBio's proficiency in checkpoint receptor signaling and proprietary biotechnology methods for generating exceptional agonist antibodies synergizes seamlessly with Gilead's drug development and therapeutic area knowledge, signifying a strategic leap forward in the application of biotechnological advancements for treating immune-related conditions

• In November 2022, AstraZeneca announced acquisition of Neogene Therapeutics Inc. into its portfolio, united in its mission to introduce cutting-edge cell therapies to patients battling solid tumors. With a shared commitment to advancing biotechnological approaches, the inclusion of TCR-Ts (cell therapy) from Neogene brings the potential to identify intracellular targets, including cancer-specific mutations, thus opening new possibilities for targeting previously inaccessible markers through cell therapies. This strategic collaboration holds great promise in transforming the landscape of cancer treatment and personalized medicine.

Biotechnology Market Report Scope

Global Biotechnology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the biotechnology market on the basis of technology, application and regions

• Technology Outlook (Revenue, USD Billion, 2018 - 2030)

  • Nanobiotechnology

  • Tissue Engineering and Regeneration

  • DNA Sequencing

  • Cell-based Assays

  • Fermentation

  • PCR Technology

  • Chromatography

  • Others

• Application Outlook (Revenue, USD Billion, 2018 - 2030)

  • Health

  • Food & Agriculture

  • Natural Resources & Environment

  • Industrial Processing

  • Bioinformatics

  • Others

• Regional Outlook (Revenue, USD Billion, 2018- 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Thailand

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait